PEPG · NASDAQ · Biotechnology

PepGen (PEPG)

Develops peptide-enabled oligonucleotide therapies with a clinical focus on myotonic dystrophy type 1.

$2.79
vs last close−0.19 (−6.54%)

Something off on this page? Send us feedback.

Next report
Nov 11, 26
in 49 days
EPS estimate
−$0.27
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.68−$0.92−$0.70−$0.52−$0.27−$0.26−$0.26Pending
Estimate−$0.81−$0.72−$0.85−$0.63−$0.40−$0.31−$0.28−$0.27
Surprise+16.0%−27.8%+17.6%+17.5%+32.5%+16.1%+8.6%

RevenueReportedEstimate

Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2027−$0.21
Sep 2027−$0.21
Jun 2027−$0.21
Mar 2027−$0.24
Dec 2026−$0.29
Nov 2026−$0.27
Aug 2026−$0.28−$0.26+8.6%
May 2026−$0.31−$0.26+16.1%
Mar 2026−$0.40−$0.27+32.5%
Nov 2025−$0.63−$0.52+17.5%
Aug 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
Jun 2022
Dec 2021
Sep 2021
Jun 2021
Mar 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020

The latest year is open to everyone — the 22 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2027−$0.21$0
Sep 2027−$0.21$0
Jun 2027−$0.21$0
Mar 2027−$0.24$0
Dec 2026−$0.29$0
Nov 11, 2026−$0.27$0
Aug 6, 2026−$0.28−$0.26+8.6%+21.7%
May 12, 2026−$0.31−$0.26+16.1%−1.2%
Mar 4, 2026−$0.40−$0.27+32.5%+5.3%
Nov 12, 2025−$0.63−$0.52+17.5%+10.3%
Aug 7, 2025
May 8, 2025
Feb 24, 2025
Nov 7, 2024
Aug 8, 2024
May 14, 2024
Mar 6, 2024
Nov 8, 2023
Aug 8, 2023
May 11, 2023
Mar 23, 2023
Nov 10, 2022
Aug 12, 2022
Jun 16, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020

The latest year is open to everyone — the 22 quarters behind it read with an account.